Rani Therapeutics Files 8-K

Ticker: RANI · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1856725

Rani Therapeutics Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyRani Therapeutics Holdings, Inc. (RANI)
Form Type8-K
Filed DateOct 16, 2024
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001, $3.00, $2.9999, $10.0 m
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, 8-K

TL;DR

Rani Therapeutics filed an 8-K on 10/15/24. Standard corporate update.

AI Summary

Rani Therapeutics Holdings, Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices located at 2051 Ringwood Avenue, San Jose, California.

Why It Matters

This filing provides an official update on Rani Therapeutics' corporate status and events, which is important for investors and stakeholders to stay informed about the company's regulatory compliance and operational disclosures.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational information that would immediately impact risk.

Key Numbers

  • 001-40672 — SEC File Number (Identifies the company's filing with the SEC)
  • 86-3114789 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Rani Therapeutics Holdings, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • 2051 Ringwood Avenue, San Jose, California 95131 (address) — Principal executive offices
  • October 15, 2024 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 15, 2024.

When was the earliest event reported in this filing?

The earliest event reported was on October 15, 2024.

In which state is Rani Therapeutics Holdings, Inc. incorporated?

Rani Therapeutics Holdings, Inc. is incorporated in Delaware.

What is the company's principal executive office address?

The principal executive offices are located at 2051 Ringwood Avenue, San Jose, California 95131.

What is the SEC file number for Rani Therapeutics Holdings, Inc.?

The SEC file number is 001-40672.

Filing Stats: 1,237 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2024-10-16 06:06:59

Key Financial Figures

  • $0.0001 — stered Class A common stock, par value $0.0001 per share RANI The Nasdaq Stock Mar
  • $3.00 — ance and will have an exercise price of $3.00 per share. The combined offering price
  • $2.9999 — or in the case of pre-funded warrants, $2.9999 per pre-funded warrant and accompanying
  • $10.0 m — fering are expected to be approximately $10.0 million, before deducting placement agent

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Rani Therapeutics Holdings, Inc. Date: October 16, 2024 By: /s/ Svai Sanford Svai Sanford Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.